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Time to revisit the deﬁnition and clinical
criteria for anaphylaxis?
Paul J. Turnera,b*, Margitta Wormc, Ignacio J. Ansoteguid, Yehia El-Gamale,
Montserrat Fernandez Rivasf, Stanley Finemang, Mario Gellerh, Alexei Gonzalez-Estradai,
Paul A. Greenbergerj, Luciana K. Tannok,l,m, Mario Sánchez Borgesn, Gianenrico Sennao,
Aziz Sheikhp, Bernard Y. Thongq, Motohiro Ebisawar and Victoria Cardonas, On behalf of the
WAO Anaphylaxis CommitteeAnaphylaxis represents the severe end of the allergic reaction, and acknowledge the spectrum
spectrum of allergic reactions. A number of
different deﬁnitions for anaphylaxis are currently
found in the literature (Table 1).1–6 Many deﬁne
anaphylaxis as a life-threatening reaction. Howev-
er, data from large case series and patient regis-
tries have demonstrated that despite the fact that
the vast majority of anaphylaxis reactions are not
treated appropriately with prompt administration
of epinephrine/adrenaline, in general this does not
result in increased mortality or morbidity (such as
hospitalization)7–9; this observation is also
consistent with national epidemiological data for
food anaphylaxis, which indicate that fatal
anaphylaxis is a rare (but unpredictable) event.10–
12 Therefore, the majority of anaphylaxis
reactions cannot be described as life-threatening
in themselves, although due to our inability to
predict severity of reaction,12 we emphasize that
all anaphylaxis must be appropriately treated
with intramuscular epinephrine/adrenaline. Both
the descriptions used by the Australasian Society
of Clinical Immunology and Allergy (ASCIA)4 and
National Institute of Allergy and Infectious
Disease (NIAID)5 refer to anaphylaxis as a seriousaNational Heart & Lung Institute, Imperial College London, London, UK
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anaphylaxis to be life-threatening.
In 2005, the Second NIAID/Food Allergy and
Anaphylaxis Network symposium proposed
clinical criteria for diagnosing anaphylaxis,5 which
were subsequently adopted by the World Allergy
Organization (Table 2).1 Of note, these criteria are
not a deﬁnition, but rather, an aid to diagnosis. At
the time, it was acknowledged that the criteria
were designed to correctly identify at least 95%
of anaphylaxis (i.e. with a sensitivity of >95%);
however, the authors identiﬁed the “need to
establish their utility and determine whether
there is need for further reﬁnement in prospective
multicenter clinical surveys”.5
The passage of time is testament to the utility of
these criteria for diagnosis and research, however
more recently it has become clear that some
reﬁnement to the above deﬁnitions and criteria
might be helpful (as acknowledged in the original
publication). In particular, the concept of equating
anaphylaxis with a systemic or multi-organ reaction
is potentially problematic. This is because:
 Anaphylaxis often involves isolated respiratory or
cardiovascular symptoms: in a large prospective
cohort of anaphylaxis presenting to an emergency
department, 31% and 14% of cases had isolated
respiratory or cardiovascular symptoms in isola-
tion, respectively.13 Indeed, such a presentation is
not uncommon in fatal anaphylaxis, both due to
food and other allergens,14,15 and is becoming
increasingly recognised in the context of oral
immunotherapy, yet by the current NIAID/FAAN
WAO1 EAACI2 AAAAI/ACAAI3 ASCIA4 NIAID5 WHO ICD-116
A serious life-
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than one organ
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Table 1. Current deﬁnitions of anaphylaxis in the literature
Anaphylaxis is highly likely when any one of the following 3 criteria are fulﬁlled:
1. Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or
both (eg, generalized hives, pruritus or ﬂushing, swollen lips-tongue-uvula)
AND AT LEAST ONE OF THE FOLLOWING
a. Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced PEF, hypoxemia)
b. Reduced BP or associated symptoms of end-organ dysfunction (eg, hypotonia (collapse], syncope,
incontinence)
2. Two or more of the following that occur rapidly after expo sun; to a likely allergen for that patient
(minutes to several hours):
a. Involvement of the skin-mucosal tissue (eg, generalized hives, itch-ﬂush, swollen lips-tongue-uvula)
b. Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced PEF, hypoxemia)
c. Reduced BP or associated symptoms (eg, hypotonia [collapse], syncope, incontinence)
d. Persistent gastrointestinal symptoms (eg, crampy abdominal pain, vomiting)
3. Reduced BP after exposure to known allergen for that patient (minutes to several hours):
a. Infants and children: low systolic BP (age speciﬁc) or greater than 30% decrease in systolic BPa
b. Adults: systolic BP of less than 90 mm Hg or greater than 30% decrease from that person's baseline
Table 2. Clinical criteria for the diagnosis of anaphylaxis, proposed at the Second National Institute of Allergy and Infectious Disease/Food
Allergy and Anaphylaxis Network (NIAID/FAAN) symposium, 2005. PEF, Peak expiratory ﬂow; BP, blood pressure. a. Low systolic blood pressure for
children is deﬁned as less than 70 mm Hg from 1 month to 1 year, less than (70 mm Hg þ [2  age]) from 1 to 10 years, and less than 90 mm Hg from 11 to 17 years
2 Turner et al. World Allergy Organization Journal (2019) 12:100066
http://doi.org/10.1016/j.waojou.2019.100066criteria, reactions with only respiratory symptoms
do not meet the criteria for diagnosing
anaphylaxis.
 It is difﬁcult to describe isolated respiratory
symptoms as generalized or systemic. If an
allergen provokes acute bronchoconstriction
that is life-endangering in the absence ofother symptoms, then anaphylaxis must be
considered as a diagnosis and, more impor-
tantly, the reaction should be managed
accordingly.
 Allergic reactions may, for example, involve skin
manifestations remote to the site of allergen
exposure – and are therefore almost certainly a
Volume 12, No. 10, October 2019 3systemic manifestation – but in the absence of
other symptoms such reactions would not
necessarily be classiﬁed as anaphylaxis.
Furthermore, there is emerging evidence that
even mild, non-generalized allergic reactions
can involve underlying systemic immune acti-
vation. Therefore, not all systemic reactions are
currently classiﬁed as anaphylaxis.16
 Some triggers of anaphylaxis cause rapidly
progressing symptoms, but are of delayed onset
after allergen exposure e.g. alpha-gal, in which
reactions can occur up to 10 hours after allergen
ingestion.17
The lack of deﬁnition for “persistent” when
applied to gastrointestinal symptoms in the current
NIAID/FAAN framework (Table 2) is unhelpful: is
“persistent” 10, 20, 60 minutes, or even longer?
This matters in terms of patient management,
clinical audit and research – does an allergic
reaction resulting in persistent nausea and skin
symptoms constitute anaphylaxis? Should a
patient who develops generalized urticaria and
vomiting after an insect sting or subcutaneous
immunotherapy be treated as anaphylaxis, as
according to the current criteria such symptoms
would need to become persistent to meet the
deﬁnition of anaphylaxis.
There has long been a discrepancy between the
inclusion of gastrointestinal symptoms as a
deﬁning feature of food-induced anaphylaxis in
North America, but not in Australia18 or the United
Kingdom,19 on the basis that with food allergens,
gastrointestinal symptoms are the result of local
allergen exposure (as opposed to the same
symptoms resulting from parenteral exposure,
which would be considered to representFig. 1 Spectrum of symptom severity in hypersensitivity reactions and
Media Kits; informed consent received.anaphylaxis). Thus, reactions to food allergens
involving skin and gastrointestinal symptoms
would not be termed anaphylaxis in these
regions, and would not usually be treated with
epinephrine/adrenaline. This lack of consistency
creates signiﬁcant methodological issues when
undertaking research to better understand the
response (or lack of) to rescue treatment etc.,
hampering improvements in anaphylaxis care.
Therefore, the Anaphylaxis Committee of the
World Allergy Organization (WAO) propose the
following revisions to the deﬁnition and criteria
relating to anaphylaxis:A REVISED DEFINITION FOR
ANAPHYLAXIS
“Anaphylaxis is a serious systemic hypersen-
sitivity reaction that is usually rapid in onset
and may cause death. Severe anaphylaxis is
characterized by potentially life-threatening
compromise in breathing and/or the circula-
tion, and may occur without typical skin fea-
tures or circulatory shock being present.”
Rationale: Anaphylaxis lies along the spectrum
of severity in terms of the extent of symptoms
(Fig. 1), ranging from mild-moderate respiratory
symptoms to circulatory “shock” and/or collapse
(“anaphylactic shock”). This description encom-
passes a more nuanced approach, consistent with
the evidence base relating to severe and fatal
anaphylaxis, that not every anaphylaxis reaction is
life-threatening. However, given our inability to
predict severe reactions and evidence thatanaphylaxis. Images courtesy of Pete Smith, MBBS, PhD, Medical
4 Turner et al. World Allergy Organization Journal (2019) 12:100066
http://doi.org/10.1016/j.waojou.2019.100066early adrenaline may help reduce risk,12 all
anaphylaxis reactions (irrespective of severity)
demand appropriate treatment with intramuscular
epinephrine/adrenaline. The description also
highlights the possibility of anaphylaxis occurring in
the absence of skin involvement or cardiovascular
shock.14A REFINEMENT OF THE WAO/NIAID/
FAAN CLINICAL CRITERIA FOR THE
DIAGNOSIS OF ANAPHYLAXIS
The WAO Anaphylaxis Committee propose to
amend the current NIAID/FAAN criteria, as shown
in Table 3. Our aim is to simplify the existing
criteria, by combining the ﬁrst two NIAID/FAAN
criteria and modifying the third to give 2 scenarios:
1. Typical skin symptoms AND signiﬁcant symp-
toms from at least 1 other organ system; OR
2. Exposure to a known or probable allergen for
that patient, with respiratory and/or cardiovas-
cular compromise.
Rationale: Given the uncertainty over the deﬁ-
nition of “persistent” gastrointestinal symptoms
discussed above, this wording has been modiﬁed
to “severe gastrointestinal symptoms (e.g. severe
crampy abdominal pain, repetitive vomiting),
especially after exposure to non-food allergens”.
This acknowledges that gastrointestinal symptoms,
particularly after exposure to non-food allergens,Anaphylaxis is highly likely when any one of the follo
1. Acute onset of an illness (minutes to several hours
both (e.g. generalized hives, pruritus or ﬂushing, s
AND AT LEAST ONE OF THE FOLLOWING:
a. Respiratory compromise (e.g. dyspnea, wheeze
b. Reduced BP or associated symptoms of end-org
incontinence)
c. Severe gastrointestinal symptoms (e.g. severe c
especially after exposure to non-food allergens
2. Acute onset of hypotension* or bronchospasm or l
highly probable allergenb for that patient (minute
skin involvement.
Table 3. Amended criteria for the diagnosis of anaphylaxis, proposed
BP, blood pressure.*Hypotension deﬁned as a decrease in systolic BP greater tha
systolic BP less than (70 mmHg þ [2 x age in years])ii. Adults: systolic BP less tha
odynophagia. b. An allergen is a substance (usually a protein) capable of triggering
through an IgE-mediated pathway, but some non-allergen triggers can act indepen
allergic reactions occur within 1–2 hours of exposure, and usually much quicker. Rea
of immunotherapy, occurring up to 10 hours after ingestion.”are indicative of anaphylaxis, without requiring
such symptoms to become persistent in order to
be treated appropriately. The choice of “severe”
rather than “persistent” is also consistent with the
grading system for allergic reactions used within
the US-based Consortium of Food Allergy
Research (CoFAR).20
The second criterion reﬂects the reality that the
occurrence of objective respiratory signs in isola-
tion following exposure to a known allergen, is
indicative of anaphylaxis.
Importantly, these criteria do not preclude the
treatment of early, but potentially evolving sys-
temic reactions in the context of allergen immu-
notherapy (particularly via the sub-cutaneous
route) as anaphylaxis.SUMMARY
The WAO Anaphylaxis Committee present to
our global colleagues the above deﬁnition and
clinical criteria for the diagnosis of anaphylaxis, our
aim being to better capture the reality of anaphy-
laxis presentations, simplify diagnosis and there-
fore improve the management of anaphylaxis.Funding
None.wing 2 criteria are fulﬁlled:
) with involvement of the skin, mucosal tissue, or
wollen lips-tongue-uvula)
-bronchospasm, stridor, reduced PEF, hypoxemia)
an dysfunction (e.g. hypotonia [collapse], syncope,
rampy abdominal pain, repetitive vomiting),
aryngeal involvementa after exposure to a known or
s to several hoursc), even in the absence of typical
by the WAO Anaphylaxis Committee, 2019. PEF, Peak expiratory ﬂow;
n 30% from that person's baseline, OR.i. Infants and children under 10 years:
n <90 mmHg. a. Laryngeal symptoms include: stridor, vocal changes,
an immune response that can result in an allergic reaction. Most allergens act
dent of IgE (for example, via direct activation of mast cells). c. The majority of
ctions may be delayed for some food allergens (e.g. alpha-gal) or in the context
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